About us

Globally, noncommunicable diseases (NCDs) accounted for 71% of total deaths. In India, NCDs were estimated to account for 63% of all deaths, and cancer was one of the leading causes (9%). India falls in the low-middle category; cancer cases and deaths were the highest in low and low-middle SDI countries and regions. By 2040, researchers predict that more than two-thirds of the world’s cancer cases will occur in low- and middle-income countries. The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020. Surgery is an important treatment option for cancer because it gives them the best chance of survival. However, sometimes the microscopic pieces of the cancers are not visible to the naked eye. In neurosurgery, it is of utmost importance to achieve maximal safe resection while minimizing iatrogenic neurologic deficit. Recently, the fluorescence-guided surgery has emerged as a cost-effective method to accurately visualize neoplastic areas in real-time to guide resection. We have established this technology at Purdue University and one of our drug Cytalux approved by FDA on November 21 st 2021 for the fluorescence guided surgeries of folate receptor positive ovarian cancer and December 16 th 2022 for lung cancer. Because of lack of efficacy of one drug-one target, the new concept “one drug-multi target” evolved as an innovative medicine. Smole Biopharma will be efficiently exploiting the multi-target profiles of small organic molecules to establish the design and development of a universal multi-receptor targeting near-infrared imaging agent for the fluorescence guided surgeries of different types and stages of cancers.

Leadership team